Development of tEAE in SJL/J Mice Treated With Anti–E-Selectin and Anti–P-Selectin MoAbs
| Treatment . | No. of Animals . | No. of Animals Developing Clinical Disease . | Mean Day of Onset of Clinical Disease4-150 . | No. of Animals With Detectable Infiltrates in CNS4-151 . |
|---|---|---|---|---|
| ⊘ | 2 | 2 | 8 | 2 |
| IgG | 5 | 5 | 8 + 0.5 | 5 |
| anti-MHC II | 2 | 1 | 9 | 1 |
| anti-CD4 + anti-MHC II | 3 | 0 | no disease | 0 |
| PS/2 | 5 | 1 | 14 | 1 |
| RB40 + UZ4 | 5 | 5 | 7.5 + 0.5 | 5 |
| Treatment . | No. of Animals . | No. of Animals Developing Clinical Disease . | Mean Day of Onset of Clinical Disease4-150 . | No. of Animals With Detectable Infiltrates in CNS4-151 . |
|---|---|---|---|---|
| ⊘ | 2 | 2 | 8 | 2 |
| IgG | 5 | 5 | 8 + 0.5 | 5 |
| anti-MHC II | 2 | 1 | 9 | 1 |
| anti-CD4 + anti-MHC II | 3 | 0 | no disease | 0 |
| PS/2 | 5 | 1 | 14 | 1 |
| RB40 + UZ4 | 5 | 5 | 7.5 + 0.5 | 5 |
Only animals developing clinical disease were taken into account.
Animals were sacrificed 3 days after onset of clinical disease; animals in the treatment groups anti-CD4/MHC II and PS/2 were sacrificed at days 10 postimmunization (p.I.), 12 p.I., and 15 p.I. respectively; animals in the treatment group anti-MHC II were killed at days 10 and 15 p.I.